Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 5227-5235

  Gatza, Erin ^a   Okada, Craig Y ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; KEYHOLE LIMPET HEMOCYANIN; QS 21; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ID PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CELL LINE; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RUGBY; T CELL LYMPHOMA; TH1 CELL; TUMOR IMMUNITY;

EID: 0036839559     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.5227     Document Type: Article

References (42)

1. Timmerman, J. M., and R. Levy. 2000. The history of the development of vaccines for the treatment of lymphoma. Clin. Lymphoma 1:129.
2. Hart, D. N., and G. R. Hill. 1999. Dendritic cell immunotherapy for cancer: Application to low-grade lymphoma and multiple myeloma. Immunol. Cell. Biol. 77:451.
3. Campbell, M. J., W. Carroll, S. Kon, K. Thielemans, J. B. Rothbard, S. Levy, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139:2825.
4. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145:1029.
5. Dyke, R. J., H. McBride, A. J. George, T. J. Hamblin, and F. K. Stevenson. 1991. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell. Immunol. 132:70.
6. George, A. J., S. G. Folkard, T. J. Hamblin, and F. K. Stevenson. 1988. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 141:2168.
7. Syrengelas, A. D., and R. Levy. 1999. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol. 162:4790.
8. Kwak, L. W., M. J. Campbell. D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209.
9. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: Long-term results of a clinical trial. Blood 89:3129.
10. Okada, C. Y., C. P. Wong, D. W. Denney, and R. Levy. 1997. TCR vaccines for active immunotherapy of T cell malignancies. J. Immunol. 159:5516.
11. + T cell response. J. Immunol. 162:2251.
12. Wong, C. P., and R. Levy. 2000. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. Cancer Res. 60:2689.
13. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
14. Banchereau, J., B. Schuler-Thurner, A. K. Palucka, and G. Schuler. 2001. Dendritic cells as vectors for therapy. Cell 106:271.
15. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605.
16. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
17. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell I-associated cytokines. J. Exp. Med. 183:87.
18. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
19. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
20. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
21. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
22. Nair, S. K., D. Boczkowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
23. Song, W., H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
24. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
25. Fields, R. C., K. Shimizu, and J. J. Mule. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:9482.
26. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
27. Timmerman, J. M., and R. Levy. 2000. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 164:4797.
28. Lim, S. H., and R. Bailey-Wood. 1999. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int. J. Cancer 83:215.
29. Timmerman, J. M., D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 99:1517.
30. Offringa, R., S. H. van der Burg, F. Ossendorp, R. E. Toes, and C. J. Melief. 2000. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12:576.
31. Timmerman, J. M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507.
32. Bhardwaj, N. 2001. Processing and presentation of antigens by dendritic cells: Implications for vaccines. Trends Mol. Med. 7:388.
33. Wen, Y. J., R. Min, G. Tricot, B. Barlogie, and Q. Yi. 2002. Tumor lysate-specific cytotoxic T lymphocytes in multipte-myeloma: Promising new effector cells for immunotherapy. Blood 99:3280.
34. Goddard, R. V., A. G. Prentice, J. A. Copplestone, and E. R. Kaminski. 2001. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin. Exp. Immunol. 126:16.
35. Kirk, C. J., D. Hartigan-O'Conner, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mule. 2001. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Res. 61:2062.
36. Allison, J. P., B. W. McIntyre, and D. Bloch. 1982. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J. Immunol. 129:2293.
37. O'Neill, H. C. 1991. Radiation leukemia virus-induced T-cell lymphomas with common T-cell receptor variable region structure and similar binding specificity for retrovirus. Leukemia 5:921.
38. Tanigawa, K., N. Takeshita, G. A. Eickhoff, K. Shimizu, and A. E. Chang. 2001. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J. Immunother. 24:493.
39. Asavaroengchai, W., Y. Kotera, and J. J. Mule. 2002. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 99:931.
40. Vierboom, M. P., H. W. Nijman, R. Offringa, E. I. van der Voort, T. van Hall, L. van den Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. Melief. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:695.
41. Rosenberg, S. A., and D. E. White. 1996. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81.
42. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191:795.